We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Cycloastragenol — Astragalus-derived telomerase activator (TA-65)
The isolated telomerase-activating aglycone from Astragalus, sold as the supplement TA-65. The honest verdict: it genuinely switches on telomerase and one small industry-funded RCT lengthened telomeres, but telomere length is a surrogate — no human study shows it extends lifespan or healthspan, it raises a theoretical cancer concern, and it is expensive.
What the evidence says
Most Cycloastragenol (TA-65) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 2008–2025 with a typical study size of 117 participants.
Based on 7 studies · 1 RCT · 117 total participants
Confidence
LowBy outcome
Cycloastragenol (TA-65) has an evidence score of 3.8/10 — emerging evidence based on 7 indexed studies. The isolated telomerase-activating aglycone from Astragalus, sold as the supplement TA-65. The honest verdict: it genuinely switches on telomerase and one small industry-funded RCT lengthened telomeres, but telomere length is a surrogate — no human study shows it extends lifespan or healthspan, it raises a theoretical cancer concern, and it is expensive. Representative study: PMID 26950204.
The commonly studied dose of Cycloastragenol (TA-65) is Commercial TA-65 supplies roughly 5-25mg cycloastragenol per day (sold in proprietary 'units'); the low dose outperformed the high dose for telomere length in the one RCT. Not a standardized or proven longevity regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Explore: Best supplements for Vitality & Longevity
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Cycloastragenol genuinely activates telomerase and a single small industry-funded RCT lengthened telomeres, but telomere length is a surrogate marker — no human trial shows extended lifespan or healthspan, the studies are small and commercially linked, and telomerase activation carries a theoretical cancer concern.
Cycloastragenol is the aglycone of astragaloside IV — the small molecule purified from Astragalus membranaceus root that is the active telomerase-activating ingredient in the commercial supplement TA-65.
It is the isolated compound, not the whole-herb extract: where the parent botanical's evidence is mostly low-quality TCM combination trials, cycloastragenol's story is specifically about telomerase.
The mechanism is real and reproducible in cell systems: the foundational work (Fauce 2008) showed the related activator TAT2/cycloastragenol modestly slows telomere shortening and boosts the antiviral function of human CD8+ T cells, and the effect was abolished by a telomerase inhibitor, pinning the action to telomerase (hTERT) activation.
In adult/old mice, dietary TA-65 elongated critically short telomeres and improved some health-span markers (glucose tolerance, bone, skin) without increasing cancer incidence (Bernardes de Jesus 2011).
The human data are far thinner and largely industry-linked: an open-label pilot of the TA-65 'PattonProtocol' (Harley 2011) reported remodeling of the immune profile (fewer senescent CD8+CD28- T cells and a drop in short telomeres) mostly in CMV-positive subjects, and a single small randomized, double-blind, placebo-controlled trial (Salvador 2016, n=117) found the low dose significantly lengthened telomeres over a year.
The honest framing: telomerase activation and telomere lengthening are real but they are surrogate markers — no trial demonstrates that cycloastragenol/TA-65 extends human lifespan or healthspan, the studies are small and conducted/funded by the product's commercial backers, and activating telomerase carries a theoretical cancer concern (the same enzyme cancer cells exploit), even though the mouse work did not show increased tumors.
It is also expensive. An unproven longevity supplement with a genuine mechanism but no proven outcome.
Small-molecule activator that switches on telomerase, the enzyme that adds telomere DNA
Elongates critically short telomeres and reduces the percentage of short telomeres
Reduces senescent CD8+ T cells; rejuvenates antiviral T-cell function in cell systems
How Cycloastragenol (TA-65) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Commercial TA-65 supplies roughly 5-25mg cycloastragenol per day (sold in proprietary 'units'); the low dose outperformed the high dose for telomere length in the one RCT. Not a standardized or proven longevity regimen.
Take with food
| Form | Type |
|---|---|
| 💊TA-65 (proprietary cycloastragenol) | Recommended |
| 💊Generic cycloastragenol capsules | Alternative |
| 💊Astragalus root extract (whole-herb, much lower aglycone content) | Alternative |
Only the proprietary TA-65 formulation has human data. Purity of generic cycloastragenol products varies widely; the compound is expensive.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Taken once daily, typically in the morning with food. Marketed for continuous long-term use, but human data extend only to ~12 months.
Dose-response data unavailable. The current published research for Cycloastragenol (TA-65) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Lengthened telomeres in one small RCT — but telomere length is a surrogate, not a proven health outcome
Fewer senescent T cells in an open-label pilot; not confirmed in a controlled trial
No human study demonstrates extended lifespan or healthspan; the claim rests on surrogate markers and mouse data
Telomerase is the enzyme cancer cells exploit; activating it is a theoretical risk, though mouse work did not show increased tumors
Avoid — telomerase activation is a theoretical cancer concern; consult an oncologist
Avoid — no safety data
Immune-remodeling effects could theoretically oppose immunosuppression; data are limited
Tip: Take with food
The best time to take Cycloastragenol (TA-65) is in the morning. Taking it with food is preferred. Cycloastragenol is a saponin aglycone with modest oral bioavailability; taking it with food in the morning is the convention in the human studies.
Cycloastragenol (TA-65) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are GI upset. Use caution if any of these apply to you: Active or prior cancer (theoretical concern about telomerase activation); Pregnancy and breastfeeding (no safety data).
A lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.